InterMune CFO Unloads $203,368 in Stock (ITMN)
InterMune (NASDAQ:ITMN) CFO John Hodgman unloaded 4,724 shares of InterMune stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $43.05, for a total transaction of $203,368.20. Following the sale, the chief financial officer now directly owns 18,843 shares in the company, valued at approximately $811,191. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on ITMN shares. Analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday, August 8th. Separately, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of InterMune from $44.00 to $50.00 in a research note on Thursday, August 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. InterMune currently has a consensus rating of “Buy” and a consensus price target of $44.85.
InterMune (NASDAQ:ITMN) traded up 14.44% during mid-day trading on Wednesday, hitting $52.059. The stock had a trading volume of 12,197,448 shares. InterMune has a one year low of $10.95 and a one year high of $54.57. The stock has a 50-day moving average of $44.09 and a 200-day moving average of $34.36. The company’s market cap is $5.621 billion. InterMune also saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 9,575,169 shares, a drop of 16.4% from the July 15th total of 11,458,044 shares. Based on an average trading volume of 1,796,186 shares, the days-to-cover ratio is currently 5.3 days. Currently, 9.9% of the company’s shares are sold short.
InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the previous year, the company posted ($0.77) earnings per share. The company’s revenue for the quarter was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.73 earnings per share for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.